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ABSTRACT
Umbilical cord blood (UCB) is increasingly being used as a donor source of hematopoietic stem cells (HSCs) to
treat bloodmalignancies. Themain limitation to the widespread use of UCB is the low number ofHSCs per unit.
To compensate, a strategy of in vitro stem cell amplification has been attempted in different research laborato-
ries. The major hurdle blocking success is the creation of culture conditions that support the growth of hema-
topoietic stem cells without their differentiation. We have designed a simple culture system for stem and
progenitor cell expansion that resulted in an increased number of hematopoietic stem cells that maintain their
ability to home to the bone marrow and to permanently engraft.
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Using umbilical cord blood (UCB) as a source of
hematopoietic stem cells (HSCs) for bone marrow
transplantation is gaining greater acceptance in many
transplant centers. For pediatric unrelated bone mar-
row transplants, UCB is a primary source of stem cells
[1]. It has been estimated that 10,000 bone marrow
(BM) transplants using UCB have occurred since the
first transplant was performed on a 5-year-old patient
with Fanconi’s anemia in 1988 [2,3]. Approximately
45,000 individuals in the United States will require
bone marrow transplants this year. About 1/3 will find
a BM match within their family, while another third
will be successful using national andworldwide BMdo-
nor registries,which contain10million registrants.The
remaining third will fail to find a suitable match [4,5].
It is particularly difficult for patients of mixed eth-
nicity or minority groups to find matches from bone
marrow registries. Assuming a match is sought for
HLA-A, B, and DR (6/6 match), it is estimated that
there are over 20 million possible genotypes with
a 43% chance of finding a 6/6 match in a registry of3million donors. This does not take into consideration
the further difficulty of contacting and obtaining con-
sent once a donor is found. All of these factors explain
why only 25% to 30% of people seeking a bone mar-
row match through the worldwide registries are suc-
cessful [6]. Public UCB banks that target specific
ethnic groups or family UCB banking can provide
for an alternative source of HSCs [7]. Family banks
are advantageous in that they provide for a family
link with immediate access to the family history, com-
patibility at major and minor HLA antigens, as well as
immediate access to the stem cells for autologous and
related allogeneic use. Public cord blood banks offer
the advantage of immediately available units that are
HLA matched and are easily shipped worldwide. It is
also possible for public banks to target collections to
specific ethnic groups that would normally have diffi-
culty obtaining BM units through the regular regis-
tries. Currently, there are about 144 UCB banks
worldwide containing 2 million units [8].
The engraftment rate, disease-free survival (DFS)
rate, and relapse rate is similar between BM and
UCB. For some patient studies it has been reported927
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rates to matched BM [9-12]. Despite the advantages
of UCB, the amount of stem cells harvested from a sin-
gle umbilical cord remains a limiting factor. It has been
estimated that a minimum threshold of 3.7  107 leu-
kocytes (LKC)/kg or 1.7 105 CD341 cells/kg should
be used [13,14]. The average cord blood unit contains
109 LKC or4 106 CD341 cells, limiting the recip-
ients to pediatric patients. Thus, the ability to expand
cord blood stem cells will increase the availability of
suitable units and allow for more adult transplants.
When assessing in vitro hematopoietic stem cell
expansion it is important to determine that the cells be-
ing expanded are capable of migrating and engrafting
to the bone marrow. Although in vitro expansion has
been successful, many of these studies result in the
loss of engraftment potential [15,16]. Repopulating
hematopoietic cells consist of 2 populations: progeni-
tor cells that have limited renewal capacity and con-
tribute to short-term engraftment, and stem cells
that have a much greater capacity for self-renewal
and contribute to long-term engraftment [17]. Most
in vitro expansion protocols result in the proliferation
of progenitor cells that can be measured by colony
assays, or FACS analysis, but have limited, if any,
long-term repopulation [18-20]. Furthermore, the au-
tocrine interactions between stem cells and progenitor
cells makes it difficult to sort out whether any stem cell
proliferation that does occur is because of the direct
effect of exogenous cytokines or the indirect effect me-
diated by nonstem cells present in the initial culture
[21]. Recently, 2 studies have achieved clinically rele-
vant expansion of long-term engrafting cells (SCID
repopulating cells—SRC) from UCB [22,23].
During a BM transplant the donor HSC will un-
dergo rapid proliferation but retain their stem cell
properties, including their ability to home to the
bone marrow and engraft long term [24,25]. This indi-
cates it may be possible to expand repopulating HSC
by recapitulating the in vivo conditions in vitro. In
this report we have developed a culture system where
the balance between stem cell and mature cell prolifer-
ation and survival is shifted toward stem cell prolifera-
tion, resulting in a 3.5-fold increase of engrafting cells
from a single UCB unit.
MATERIALS AND METHODS
Maternal Blood Screening, Collection, Processing,
and Cryopreservation
Maternal blood was screened for HIV I/II,
HTLV-I/II, Hepatitis B (HBs Ag), Hepatitis C (anti-
HVC), CMV, and VDRL, and written consent for col-
lecting and processing UCB was obtained at the time
of registration. Qualified hospital personnel, following
protocols approved by the human ethics committee of
the Mt. Sinai Hospital and the University of Toronto,collected the cord blood at the time of delivery. The
blood volume was reduced and the red blood cells re-
moved with Pentaspan (starch) as described previously.
All samples were cryopreserved prior to use by storage
in liquid nitrogen [26].
Isolation of an Enriched Stem Cell or Progenitor
Cell Population
A negative selection column was used to isolate
Lineage negative cells (Linneg). The antibody mix con-
tained a set of lineage specific surface markers found
on mature hematopoietic cells; CD2, CD3, CD14,
CD16, CD19, CD24, CD56, CD66, and glycophorin
A (Stem Cell Technologies, Canada). The manufac-
tures protocol was followed. Following isolation, the
Linneg cells were used for subsequent culture manipu-
lation. For multiple reselections of cultured cells the
same technique was employed as for the original isola-
tion of Linneg cells.
Cell Culture Systems
Different cell culture systems were tested: (a)
DMEM 1 10% FBS, (b) conditioned medium (CM):
human fibroblasts (CM) grown in aMEM with 10%
FBS for 72 hours. The medium was collected and the
cells and debris were removed with centrifugation
and filtering (0.22-mm filter). (c) Nonconditioned se-
rum-free medium: IMDM, 1% bovine serum albumin,
10 mg/mL bovine pancreatic insulin, 200 mg/mL hu-
man transferring, 1024M b-mercaptoethanol, 2 mM
L-glutamine (Stemspan medium: Stem Cell Technol-
ogies), and 40 mg/mL low-density lipoproteins (LDL;
CalBiochem, San Diego, CA). Linneg cells were tested
for growth in all 3 medium, and only medium b or c
were also tested after supplementation with the follow-
ing growth factors; 25 ng/mL FGF-4, 25 ng/mL IL-3,
25 ng/mL SCF, 25 ng/mL FLT3 ligand, plus heparin
25 ng/mL. Cells were grown for 4 days to 28 days with
medium and growth factor changes made 3 times/
week. All cells were grown in FALCON brand tissue
culture treated 6, 12, or 24 well plates (Becton Dickin-
son, Franklin Lake, NJ).
Flow Cytometry Analysis
Samples were stained with antibodies to HLA-
ABC, CD34, CD38, CD33, CD4, CD19, CD56, and
CD45 (Beckman-Coulter, Fullerton, CA) and sub-
jected to flow cytometer analysis; Coulter-Epics
(Coulter, Burlington, Canada). Isotype controls were
used in all cases. All samples were labelled for 10 to
20 minutes at 4C, washed, and fixed in 10% formalin,
as per manufacture’s instructions.
Colony-Forming Cells (CFC) Plating Assay, and
LTC-IC
Apremademethylcellulose-based colony assayme-
dium (Stem Cell Technologies) was used as previously
Hematopoietic Stem Cell Amplification 929described [27].Themedium is formatted to growprim-
itive progenitors. Linneg or cultured cells were plated at
500 cells per 3 mL of medium. All populations were
plated in duplicate and scored at days 12, 14, 16, and
18. Day 16 data is represented in the figure. Cells
were also tested for primitive progenitor cells by
LTC-IC protocol as previously described [27].
Nonobese Diabetic (NOD)/SCID Mouse
Engraftment
NOD/SCID mice were used to test the engraft-
ment potential of the human UCB stem cells [27].
All experiments followed established protocols and re-
ceived animal ethics approval. The mice were irradi-
ated 2 hours before engraftment at 360 Rads using
a Cs137 source. The mice were then injected by tail
vein with 100 mL of cell solution with varying amounts
of cells to establish a limiting dilution assay. Survival
rate was .80% per experiment. At 8 weeks, animals
were euthanized and the bone marrow was flushed
from the femurs. Cells were washed in PBS and the
cell pellet was subjected to Red Cell Lysis Buffer for
3 minutes and washed again. Cells were analysed by
flow cytometry using antibodies against HLA-ABC
and CD45.
Statistical Analysis
The expansion of SRC was quantified using limit-
ing dilution analysis. The frequency of SRC was cal-
culated by using the maximum likelihood estimator
as previously described. The assumption was made
that every individual stem cell was capable of engraft-
ing a mouse. Because pooled data was used we calcu-
lated c2 values for the data and determined they were
not significant (P . .05), indicating that pooling of
data between experiments was valid [28,29]. A Stu-
dent’s t-test was used to determine statistical signifi-
cance for each of the specific colony types observed
at day 0 and day 8 for the CFC and LTC-IC assays
(P\ .05).
RESULTS
Development of a Serum-Free and Feeder Cell-
Free Culture System That Supports the Expansion
of HSC That Are Capable of Multilineage
Differentiation
To increase HSC during in vitro culture we devel-
oped a system that does not cause a substantial increase
in mature cells, therefore reducing their negative im-
pact on the HSC. Although serum and feeder cells
are not ideal for clinical applications they have been
used successfully for themaintenance and proliferation
of both embryonic stem cells andHSC [30,31]. Pheno-
typic and functional assays were used to track changes
in cell composition during culture with serum and/or
conditioned medium. Because the manipulation ofUCB units to isolate stem cells results in an initial
loss of stem and accessory cells it is important that
expansion technology is robust enough to generate
stem cells in numbers that are significantly greater
than the initial number of cells in the unmanipulated
cord blood unit, and that there is also regeneration
of progenitor cells, because they act as accessory cells
in support of the engraftment process. To determine
whether our expansion conditions results in a net
increase in engrafting cells and accessory cells we mea-
sured the frequency of CD451, CD341, and CD341/
382 cells, as well as CFCs, LTC-ICs, and SRCs of
unmanipulated UCB, Linneg day 0 cells and day 8 ex-
panded Linneg cells. This strategy allowed us to follow
phenotypic and functional properties of the cells dur-
ing culture. Because CD341 cells represent a broad
spectrum of progenitor and stem cells, CFCs were em-
ployed to characterize the progenitor cell population
and LTC-IC and SRC assays were employed to define
cells capable of homing and providing long-term
engraftment.
For all experimentsUCB units were pooled. An av-
erage UCB unit contains 1 109 viable total nucleated
cells (TNC) (n 5 255). All experiments were normal-
ized to represent a single cord blood unit, and all cells
were plated at 100,000 cells/mL. Initially we tested the
ability of media containing 10% FBS or human fibro-
blast conditioned medium (CM) without growth fac-
tor supplementation to support HSC growth. Cells
died within 48 to 72 hours of plating (data not shown).
Therefore, the serum containing medium alone, even
if preconditioned, was not capable of supporting
stem cell proliferation. Combinations of growth fac-
tors were added to the CM cultures to investigate their
ability to support HSC growth. Cells were tested
initially at days 0, 8, and 15 days of culture. Media
was exchanged every 2 days, and no reselection or
cell removal occurred during the culture period. The
addition of Fgf-4 allowed for a 3.3-fold increase in
the total cells as indicated by CD451 detection as
well as a 3.7-fold increase of CD341 cells at day 15
(n 5 6) (Figure 1). When the CM was supplemented
with FGF-4, SCF, and Flt3-ligand (CM 1 FSFl),
a 22-fold increase of the CD451 cells by day 15 was
observed, but the CD341 cells had only expanded
3.8-fold (n 5 3) (Figure 1). The increase in CD451
cells without an appreciable increase in the CD341
population demonstrated that the cells were differenti-
ating in culture. Despite the addition of growth factors
the presence of unknown factors in the serum and con-
ditionedmedium caused the differentiation of the stem
cells without any appreciable stem cell expansion.
Because the serum-containing medium was not
advantageous for stem and progenitor cell growth,
we investigated the ability of a defined, serum-free me-
dium with growth factor supplementation to support
stem and progenitor cell renewal and expansion.
930 I. M. Rogers et al.Because the FGF-4, SCF, and Flt3-ligand supplemen-
tation did demonstrate some stem cell expansion we
tested this growth factor combination with serum-
free and CM-free medium (FSFl). Linneg UCB
cells cultured with FGF-4, SCF, and Flt3-ligand-
supplementedmediumwithout CMgrewmore rapidly
than their CM counterparts, and the CD34 cells
increased at a rate similar to the total cell population
(n 5 9) (Figure 1). Under serum-free and CM-free
conditions an 11- and 12.7-fold expansion of CD341
and CD451 cells, respectively, was achieved at day 8,
and a 24-fold expansion for CD341 cells and 34-fold
expansion for CD451 cells occurred at day 15. This
demonstrates that the serum-free and CM-free culture
is capable of supporting stem cell growth.
Cultures were also monitored at day 0 and day 8 by
CFC and LTC-IC to determine the ability of serum
and CM-free medium supplemented with Fgf-4,
SCF, and Flt3-ligand (FSFl) to support stem and pro-
genitor cells. FSFl culture resulted in the proliferation
of cells resulting in a 16-fold amplification in 8 days.
Because there was no significant difference in the num-
ber of colonies produced per 500 cells plated for day
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Figure 1. Serum containing medium or conditioned medium pre-
vents stem and progenitor cell proliferation. Medium conditioned
with human embryonic fibroblast cells was supplemented with
Fgf-4 alone (n5 6) or FgF4/SCF/Flt3-ligand (n5 3). Cells were as-
sayed for CD341 cells and CD451 cells at day 0, day 8, and day 15 of
culture. Fgf-4 supplementation had little effect on the proliferation
rates of the total cells (CD451, 3.3-fold at day 15) or the stem/pro-
genitor subset (CD341, 3.7-fold at day 15). Supplementation with 3
growth factors positively affectedCD451 cells (22-fold at day 15) but
had little effect on the CD341 subset (3.8-fold at day 15). The serum
and conditionedmedium had an inhibitory effect on stem cell ampli-
fication as demonstrated by the increase in CD341 cells in serum-
free, CM-free conditions (n 5 9). There was a 24-fold increase in
CD341 cells and 34-fold for CD451 cells at day 15.0 and day 8 cultured cells, the calculated increase in
CFCs was 16-fold. The LTC-IC from the cultured
cells produced 23% less colonies compared to the
Linneg cells (day 0) (equivalent number of cells plated)
and after normalization to day 0 cells the overall in-
crease in LTC-IC cells was 7.3-fold. The composi-
tions of the colonies from the LTC-IC assay were
similar for day 0 cells and day 8 cells. Both cell popu-
lations were capable of producing macrophages, gran-
ulocyte, erythrocyte, mast cells, and esonophils,
demonstrating that the FSFl culture system supports
the propagation of all progenitor cells types demon-
strating that the amplified stem cells are capable of
multilineage differentiation (Figure 2A and B).
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Figure 2. Composition of input cells is equivalent to the cultured
cells at day 8. (A) CFCs measure the differentiation potential of
the progenitor cells contained in the culture. At each culture time
point (t 5 0, n 5 4 and t 5 8 days, n 5 6) the number of colonies
per 500 cells plated (Y-axis) and the composition of the colonies
(X-axis) was not statistically significant from each other, indicating
that the culture process supported the growth of progenitor cells
(P\ .05). Colonies were scored at days 12, 14, 16, and 18 to observe
the ideal colonymaturation point. Day 16 results are represented. (B)
Day 0 cells and day 8 cultured (FSFl) cells were assayed for their stem
and progenitor cell content using the LTC-IC assay (n 5 7). There
was a 23% decrease in the total number of colonies produced by the
day 8 cells (per 500 cells plated) (Y-axis) but the composition was not
significantly different between the 2 cell populations (P \ .05).
When normalized to Linneg cells (day 0) the expansion of LTC-IC
cells was 7.3-fold.
Hematopoietic Stem Cell Amplification 931NOD/SCID Mouse Engraftment with FGF-4/SCF/
Flt3L Cultured Cells
Our in vitro studies clearly demonstrate an
increase in stem cell numbers during an 8-day culture
period as tested by CD341 cells, CFCs, and LTC-ICs,
but the true test is the presence of SRC. Furthermore,
it is important to determine whether the cultured cells
have the ability to home to the bone marrow, as this is
critical for successful engraftment in humans. To ad-
dress the homing and engraftment potential of our in
vitro expanded stem cells we used a long-term engraft-
ing limiting dilution assay (LDA) to determine the fre-
quency of long-term SRC using the TNC population
from an unmanipulated UCB unit, Linneg cells, and
day 8 grown Linneg cells. This allowed us to compare
the frequency of SRC from each population. A com-
parison between TNC and Linneg cells allowed us to
calculate the loss of SRC that occured during stem
cell isolation. Comparison of the SRC from the
cultured cells to the frequency of SRC in the TNC
population allowed us to determine if our culture con-
ditions result in significantly more SRC, even though
some loss occurs during the initial isolation of Linneg
cells. Sublethally irradiated NOD/SCID mice re-
ceived different doses of cultured or noncultured cells.
Mice were sacrificed at 8 weeks posttreatment, and the
cells were analyzed for human cell content by flow
cytometry using antibodies specific for human HLA-
ABC and human CD45 as previously described
[26,27]. It has been previously reported that HSC are
lost during isolation of Linneg cells using a gravity-
based negative selection column [22]. The calculation
of the frequency of SRC for each of the 3 cell popula-
tions confirms that SRC are lost during the initial
isolation step, but despite this initial loss our culture
conditions yielded an increased number of SRC. Based
on the LDA, the frequency of SRC in the TNC popu-
lation is 1/15  106 cells (95% confidence interval,
1/9.6  106-1/25.6  106). Because the average UCB
unit contains 109 cells, this translates into 67 SRC/
UCB unit. The frequency of SRC for Linneg day 0 cells
was 1/40,647 (95% confidence interval, 1/21,942-1/
78,590). Because the yield of Linneg cells from 1  109
UCB cells (one UCB unit) is 0.235% or 2.35  106
cells (n 5 10), a frequency of 1/40,647 equals 58
SRC from a single UCB unit after Linneg cell selection.
This represents a loss of 9 SRC (13.4%) because of the
isolation process. This is inline with previous reports
[22]. For the FSFl cultured cells (day 8) the frequency
of SRC was 1/98,544 (95% confidence interval, 1/
59,870-1/168,500) (Figure 3). The average expansion
of the cultures for these experiments during the 8
day culture was 9.8-fold (n 5 10). Therefore, the final
culture product yielded 233 SRC perUCB unit [Linneg
cells/UCB unit day 0 5 2.35  106. Increase of 9.8-
fold after 8-day culture 5 23.03  106 cells. The fre-quency of SRC after culture was 1/98,544; therefore,
there are 233 SRC in the final culture product: (2.35
million cells  9.8 5 23.03million cells/98,544 5
233). This is an increase of 3.5-fold over the TNC
population. Even with a loss of Linneg cells during
the isolation process this is a significant expansion
TNC
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Figure 3. Positive NOD/SCID engraftment with cultured derived
stem cells. UCB-derived stem cells amplified in culture maintain
their ability to home to the bone marrow and engraft long term. A
limiting dilution assay demonstrates that a 4-fold increase of long-
term populating cells occurs in the serum-free, feeder cell-free cul-
ture system supplemented with FGF4, SCF, and Flt3-ligand during
an 8-day culture period over Linneg cells (day 0). Some Linneg cells
are lost during the isolation process. Comparing the frequency of
SRC from unmanipulated UCB (TNC) to Linneg cells (day 0) dem-
onstrated that 13.4%of the SRC are lost. Real expansion (3.5-fold) is
calculated by comparing the frequency of SRC in the unmanipulated
unit (TNC) to the cultured cells normalized to a single UCB unit
equivalent. Day 0 Linneg cells: cell dose: 30,000 (n 5 3), 55,000
(n 5 5), 110,000 (n 5 9). FSFl cells: cell dose: 50,000 (n 5 5),
100,000 (n 5 4), 200,000 (n 5 14), 275,000 (n 5 4). TNCs: 40 
106 (n 5 2), 10  106 (n 5 29), 4  106 (n 5 9), 1.5  106 (n 5 1),
0.5  106 (n 5 2).
932 I. M. Rogers et al.of SRC and proof that FSFl medium is capable of sup-
porting stem cell proliferation without the loss of
homing or engraftment properties of the cells.
Longer Culture Times or Rapid Proliferation
Results in Reduced Stem Cell Content
Cells grown in the FSFl medium were analyzed for
the fold increase in total cells (CD451) and stem cells
(CD341) at days 0, 7, 12, 21, and 28 days to investigate
the dynamics of the cell population over time. In the
present study we analyzed cells for the presence of
CD34 and CD38. It has been demonstrated that
CD341/382 cells contain the primitive hematopoietic
cell population [32,33]. Analysis ofCD341 andCD381
cells revealed that the stem and progenitor cells differ-
entiate during culture (Figure 4A). The initial Linneg
population was comprised mainly of CD341 cells
(67%, n5 10 range: 42%-98%). This population con-
sists of 2 main subgroups; CD341/382 cells, which
designate stem cells and CD341/CD381 cells, which
designate progenitor cells. Maturing cells (CD342/
CD381) contribute only 5% of the cell population.
Interrogation of the CD342/CD382 cells at day 0
revealed that this is a mature population of cells that
consists of myelomonocytic cells (CD342/CD331),
T cells (CD4), B cells (CD19), and NK cells (CD56).
Three cultures were grown in FSFl medium. For the
first 7 days the CD341 cells proliferated with little dif-
ferentiation. In fact, the CD341 cell content increased
from 67% at day 0 to 74% of the total cells (range:
58%-93%) at day 7, suggesting that the culture condi-
tions preferentially supports CD341 cell growth over
differentiation. By day 28 the population composition
has dramatically changed with stem and progenitor
cells making up\20% of the population with the re-
mainder consisting of mature cell types. The increase
in the percentage of mature cells (CD342/382) at day
12 indicated a shift toward differentiation and away
from stem cell renewal and expansion. Day 7 and day
21 cultures cells were tested for progenitor cells by
CFCassay. A reduction in colonies from the day 21 cul-
tures compared to the day 7 cultures verifies the loss of
progenitor cells (data not shown). The initial increase
of the number of CD341 cells during the first 7 days
of culture coincides with an increase in SRCs.
To understand the culture kinetics better we tested
the serum free cultures supplemented with Fgf-4 alone
or Fgf-4, SCF, Flt-3 ligand, or Fgf-4, SCF, Flt-3
ligand plus IL-3. The cultures demonstrated a trend
in which the rate of cell proliferation was directly
correlated to the rate of differentiation. The fastest
growing cultures, as indicated by the largest increases
in total cells (CD451), did not support the amplifica-
tion of stem and progenitor cells (CD341/CD382)
(Figure 4B). Cultures supplemented with Fgf-4
only grew slowly (n 5 4). The amplification of
the CD341/382 cell subpopulation was 2.5-foldcompared to the input cells, whereas the total cell
population only expanded 1.3-fold. The percentage
of CD341/CD382 cells at day 8 was 80%. Fgf-4,
SCF, and Flt3-ligand plus IL-3 grown cells expanded
62-fold but contained only 11.3% CD341/382 cells;
therefore, the increase of CD341/382 cells was 17-
fold over input cells (n5 4). Although the combination
of Fgf-4, SCF, and Flt3-ligand resulted in a 16-fold
expansion of CD451 cells a large percentage of these
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Figure 4. Increased cell divisions either through long culture times
or rapid cell cycle results in the loss of stem cells. (A)Using the FgF4/
SCF/Flt3-ligand supplemented medium (serum and CM-free)
CD341 and CD451 cells were monitored at day 0 (n 5 16), day 7
(n 5 9), day 12 (n 5 8), day 21 (n 5 5), and day 28 (n 5 2). The in-
crease in CD341 cells peaked at day 7 of culture than declined. This
initial increase correlated with an increase in SRC. After day 12 the
percentage of CD341 declines, indicating a switch from stem cell
proliferation to differentiation. (B) Stem, progenitor, and total cell
content was compared for different culture conditions that resulted
in different rates of proliferation. The addition of IL-3 to the FSFl
cultures resulted in the largest increase of CD451 cells of all 4 con-
ditions tested (n 5 4) but the CD341/382 cell content was the low-
est, and produced a fold increase of stem cells less than the FSFl
culture. Serum-free medium supplemented with FgF4/SCF/Flt3-
ligand selectively supported the proliferation of CD341/382 cells
(n5 4). The CD341/382 cells made up 60.2% of the total cell con-
tent, resulting a net increase of 24-fold. Fgf4 alone (n5 4) produced
the cultures with the largest percentage of CD341/382 cells but with
a modest cell proliferation rate, resulting in a total CD341/382 fold
increase 1/10 that of the FSFl medium culture.
Hematopoietic Stem Cell Amplification 933cells remained CD341/382 (60.2%), the overall ex-
pansion of CD341/382 cells was 24-fold, the best
stem cell expansion overall (n 5 4) (Figure 4B).
Removal of Mature Cells Resulted in an Increase of
Linneg Cells But Did Not Improve the Recovery of
Cells with Engraftment Potential
Culture conditions that result in the proliferation
of mature cells can have a detrimental effect on stem
and progenitor cell amplification so the removal ofma-
ture cells during cell culture may be beneficial to stem
and progenitor cell expansion [21]. Although the FSFl
medium resulted in expansion of the input cells with-
out the need for removal of mature cells during the
8-day culture period, we investigated whether multiple
reselections would improve the SRC yield. Three rese-
lection regimens were tested: reselection every 4 days
or reselection every 8 days for a total of 5 reselections,
and delaying the first reselection until the 12th day of
culture followed by reselection every 8 days (Figure 5).
The latter was done to determine if the differentiation
programme was already initiated in the cells at day 12.
For the 4-day reselection the peak occurred at the third
reselection (12 days), resulting in a 13-fold increase in
Linneg cells. For the 8-day reselection Linneg cell ex-
pansion peaked at the fourth reselection (32 days),
resulting in a 16-fold increase. Delaying reselection
to day 12 resulted in a decreased Linneg cells content
that occurred after the first reselection, indicating the
Linneg cells within the culture were irreversibly in-
duced to differentiate and the removal of mature cells
at day 12 was too late.
To determine the engraftment ability of the cells
from the day 8 reselection culture we tested cells
from the fourth selection and sixth selection for their
ability to engraft NOD/SCIDmice. Post-fourth selec-
tion cells were able to engraft at low levels. Onemillion
cells/mouse were injected into 6 mice and 2 mice
engrafted after 8 weeks. In the standard day 8 FSFl cul-
ture without reselection, a lower cell dose (275,000
cells) resulted in 100% of the mice engrafting (n 5
4), indicating that the cells from the fourth reselection
have begun to lose their long-term repopulating po-
tential. None of the mice engrafted after receiving 1
million cells (n 5 4) from the sixth selection popula-
tion. Taken together, the data suggest that the mature
cells did not have an adverse effect on HSC renewal in
the FSFl cultures because their removal did not en-
hance the population of long term repopulating cells.
Culture Effects on Cell Cycle and Apoptosis Gene
Expression
The growth factors used were chosen for their abil-
ity to promote stem and progenitor cell proliferation
and inhibit apoptosis. This was confirmed by investi-
gation of the expression of cell cycle and apoptosis
genes. Inducing stem and progenitor cells to prolifer-ate in culture did not seem to trigger cell death, as
viability remained at .90%. In the current study we
investigated the expression patterns of the D cyclins,
genes involved in the G1 to S transition and the apo-
ptosis genes Mcl-1, Bcl-x long, Bax, and Bak over the
8-day culture period in FSFl medium (Figure 6).
Cyclin D1 was absent in all conditions. Cyclin D2
had observable gene expression in day 0 cells and
demonstrated a slight increase in expression over the
culture period, whereas cyclin D3 was absent at day
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Figure 5. Growth of Linneg cells in FSFl medium coupled with the
removal of mature cells does not maintain stem cell potential. (A)
Linneg cells were plated and reselected every 4 days resulting in an in-
crease in Linneg cells that peaked at the third reselection (n5 3). (B)
Reselection of cultured Linneg cells every 8 days also resulted in an
increase of the Linneg population during the first 4 reselection but
could not be maintained after this point (n 5 3). (C) Delaying the
first reselection to day 12 confirms that many of the cells have started
to differentiate and were removed with the Linpositive (mature) cell
fraction during the first reselection (n 5 2). For all 3 cultures total
cell content also declined, indicating a decrease in proliferation of
the cultured Linneg cells with time. Mice transplanted with 1 million
cells from the day 8 reselection culture after the fourth (n 5 6) and
sixth (n 5 4) selection had little or no engrafting potential. (A 5
CD451 and D 5 CD341).
934 I. M. Rogers et al.0 but was highly expressed in cultured cells at day 8,
suggesting both of these cylins are induced by the cul-
ture conditions. The antiapoptosis gene Mcl-1 had
a slight decrease in expression during culture, but
Bcl-x long, also a protector against apoptosis, showed
a marked increase in expression. Decreased expression
Figure 6. The FgF-4/SCF/Flt3 ligand promotes cell survival and
proliferation. Stem cells tend to undergo renewal cell divisions, re-
sulting in 1 stem cell and 1 progenitor cell. In vitro manipulation
of stem cells to force cell expansion can induce apoptosis resulting
in cell loss. FgF-4, SCF, and Flt3ligand were able to support stem
cell proliferation and enhance cell survival. Expression of the G1
phase cyclin gene D2 was maintained during culture while D3 was
upregulated. The ability of theses growth factors to enhance cell sur-
vival was demonstrated by the upregulation of the cell protector gene
Bcl x-long and the downregulation of the cell death genes Bax and
Bak. The overall effect was culture conditions that favor cell prolif-
eration (n 5 4).of the 2 inducers of apoptosis, Bax and Bak, occurred
with culture. Taken together, the culture conditions
used here caused an increase in cell numbers through
the promotion of the cell cycle while keeping apoptosis
in check.
DISCUSSION
HSC are capable of dividing and repopulating the
bonemarrow as demonstrated clinically in humans and
experimentally in mice and sheep [3,14]. Serial trans-
plantation of HSC in mice demonstrated that stem
cells would undergo multiple rounds of cell prolifera-
tion without loss of their engraftment potential, al-
though the animals did not always engraft to normal
levels [34,35]. Achieving similar stem cell expansion
with in vitro culture has only been successful in a few
circumstances [22,23,32]. Here, we report on the use
of a defined medium free of serum, conditioned me-
dium, or feeder cells, to achieve a 3.5-fold expansion
of long-term SCID repopulating cells from UCB.
Achieving a 3.5-fold expansion of engrafting cells is
significant for increasing the donor pool. We have
demonstrated that the mature cells that can accumu-
lated in the culture, and have been reported to have
an adverse effect on stem cell amplification can be
held in check by creating a culture environment that
supports the propagation of long-term SCID repopu-
lating cells over mature cells. The presence of unde-
fined culture components such as feeder cells,
conditioned medium, or serum containing medium re-
sulted in the rapid differentiation of the stem cells and
subsequent increase of themature cells with little or no
expansion of stem and progenitor cells. Although the
presence of cytokines can temporarily offset the factors
that have a negative influence, overall depletion of en-
grafting cells ensues [18]. Using a defined, serum-free,
feeder cell-free medium supplemented with growth
factors, allows for better control of the culture dynam-
ics. Supplementation of the medium with Fgf-4, SCF,
and Flt3-ligand resulted in SRC expansion and mini-
mal cell differentiation within an 8-day culture period.
Our culture conditions slow down the appearance of
mature cells but do not abolish them. Prolonged cul-
ture results in the buildup of mature cells to critical
levels resulting in a shift from stem cell expansion to
stem cell depletion.
The factors chosen for this studywere ideally suited
for stem cell expansion in that they were capable of
stimulating cell proliferation without differentiation,
and have the ability to act as inhibitors of apoptosis
[36-40]. This is a key requirement because cells in vitro
that are induced to divide or inhibited from differenti-
ation usually undergo apoptosis [41-43]. Specific
apoptotic factors that are known to affect the growth
of HSCs are found in the apoptosis gene family
Bcl-2. The protectors Bcl-x long and Mcl-1 and the
Hematopoietic Stem Cell Amplification 935pro-apoptotic genes, Bax andBak, regulate hematopoi-
esis. The importance of Bax as an inducer of apoptosis
in HSC is evident in Bax knockout mice, as these mice
contain increased levels of thymocytes and B cells
[44,45]. In contrast, the conditional deletion of Mcl-1
led to the reduced development of T- and B-lympho-
cytes [46]. Under our conditions Bcl-x long increases
its gene expression, whereas Mcl-1 displays a slight
decrease. At the same time, the levels of Bax and Bak
decline. These changes account for the high viability
observed.
Il-3-supplemented cultures demonstrated that
there is an inverse correlation between cell division
rate and stem cell expansion. Rapidly dividing cultures
resulted in differentiation toward mature cells at the
expense of the stem cells. Cultures containing Fgf-4,
SCF, Flt3-ligand, and IL-3 resulted in large expan-
sions of all cells over an 8-day period coupled with a re-
duced percentage of CD341/CD382 cells, whereas
the same cultures without IL-3 increased moderately
but with less differentiation, resulting in a higher abso-
lute number of CD341 cells. Cultures without IL-3
grown for longer periods of time were equivalent to
the IL-3 containing cultures. Over time cells differen-
tiated, and the accumulation of mature cells reached
critical levels, resulting in the loss of stem cells.
Using an SCID repopulating cell-limiting dilution
assay to measure expansion of long-term repopulating
cells demonstrated that a 4-fold expansion over day
0 Linneg cells occurred.When expansion was corrected
for Linneg cell loss during the column selection pro-
cess, an increase of 3.5-fold was achieved. Further-
more, infusion of the cultured cells via the tail vein
during these studies confirms that the cells do not
lose their ability to home to the bone marrow.
Although in vivo studies using mouse HSC have
demonstrated their apparent ability for infinite expan-
sion [34], our in vitro reselection studies demonstrate
that a peak in stem cell expansion is achieved early dur-
ing culture (day 8). Although we were able to achieve
the expansion of SRC, our studies demonstrate that
there is an apparent limit to stem cell expansion in
vitro. Coupling a defined growth environment with
multiple reselections did result in an enrichment of
Linneg cells, as these cells were unable to engraft. It is
possible that the SRC lost their ability to home to
the bone marrow, or that during culture the mature
cells lost surface antigens resulting in pseudo-Linneg
cells populating the culture. In this study we could
demonstrate a positive correlation between the in-
crease of CD341/CD382 cells and SRC in our culture
system at day 8. This has also been observed by Bhatia
et al. [32] but not Dorrel et al. [47]. The discrepancies
between the studies could be because of the different
culture conditions used.
Although the mechanism underlying the loss of
engraftment potential remains unclear, multiple rese-lections were not beneficial for the long-term culture.
The apparent contradiction with in vivo expansion
data suggests that despite the suitability of our culture
to support the successful proliferation of SRC the con-
ditions do not replicate perfectly the HSC niche.
We have demonstrated that our culture system us-
ing a defined medium without stem cell reselection re-
sults in an increase in long-term repopulating HSC.
Progenitor and stem cell expansion is important be-
cause we have previously reported that, on average,
75% of banked UCB samples contain sufficient cells
only for pediatric patients based on current guidelines
for cell dose [48]. Being able to expand the stem cell
content of individual cord blood units 3.5-fold will
allow for an increase in the efficacy of samples for pe-
diatric and adult patients. The expansion rate achieved
here is significant for clinical applications. The average
UCB unit (109 TNC) is acceptable for a patient weigh-
ing 27 kg (recommended cell dose of 37 million TNC/
kg). Therefore, a 3.5-fold increase in SRC will allow
for most UCB units to be used in adult patients. Un-
manipulated UCB samples have been used successfully
for adult patients, but low cell dose limits UCB donor
samples as a secondary treatment to bone marrow
donor cell transplant [11,12]. Furthermore, with the
ease of UCB collection and storage, stem cell expan-
sion of existing and new samples will allow for multiple
uses from a single donation. This will create a larger
donor pool and aid in reducing patient death rates
because of the lack of an appropriately matched donor
sample.
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